In this issue:
- Nivolumab for relapsed malignant mesothelioma
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA NSCLC
- Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma
- OS benefit with tebentafusp in metastatic uveal melanoma
- First-line pertuzumab + trastuzumab + taxane for HER2-positive breast cancer
- Second-line PD-1 inhibitors vs. chemotherapy in advanced oesophageal SCC
- VTE risk with immune checkpoint inhibitors
- Immune checkpoint inhibitor associated sarcoidosis
- Nivolumab + ipilimumab for rare gynaecological malignancies
- Pembrolizumab for persistent, recurrent or metastatic cervical cancer
Please login below to download this issue (PDF)